Department of Pediatrics, Chonnam National University Hwasun Hospital, Hwasun.
Department of Pediatrics, Chonnam National University Medical School.
J Pediatr Hematol Oncol. 2021 Apr 1;43(3):112-113. doi: 10.1097/MPH.0000000000002009.
MEF2D (myocyte enhancer factor 2D)-rearranged acute lymphoblastic leukemia (ALL) has recently been documented by transcriptome sequencing in B-cell precursor ALL. It is associated with older age of onset (median: 14 y), and characterized by very early relapse and poorer outcomes than other B-cell precursor ALL groups. According to report by Suzuki and colleagues, all 4 cases of MEF2D-BCL9-fusion ALL among 59 children with relapsed or primary refractory ALL had leukemic blasts morphologically mimicking mature B-cell leukemia cells. However, we display morphologically different blast populations in 2 patients with MEF2D-BCL9-rearranged ALL. Mature B-cell leukemia-like morphology would aid the detection of MEF2D-BCL9 fusion, but not all cases might have typical morphology.
MEF2D（肌细胞增强因子 2D）-重排急性淋巴细胞白血病（ALL）最近通过 B 细胞前体 ALL 的转录组测序被记录。它与发病年龄较大（中位数：14 岁）相关，与其他 B 细胞前体 ALL 组相比，其复发更早且预后更差。根据铃木和同事的报告，在 59 例复发或原发性难治性 ALL 儿童中，有 4 例 MEF2D-BCL9 融合 ALL，其白血病细胞形态上类似于成熟 B 细胞白血病细胞。然而，我们在 2 例 MEF2D-BCL9 重排 ALL 患者中显示出形态不同的原始细胞群体。成熟 B 细胞白血病样形态有助于检测 MEF2D-BCL9 融合，但并非所有病例都可能具有典型形态。
